Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Pfizer Inc Amendment

23 Nov 2015 15:34

RNS Number : 6649G
JPMorgan Asset Management
23 November 2015
Β 

Β 

Β 

AMENDMENT

FORM 8.3

Β 

IRISH TAKEOVER PANEL

Β 

Β 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2007 (AS AMENDED)

Β 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Β 

Β 

1. KEY INFORMATION

Β 

Name of person dealing (Note 1)

JPMorgan Asset Management

Company dealt in

Pfizer Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares

Date of dealing

19 November 2015

Β 

Β 

2. INTERESTS AND SHORT POSITIONSΒ 

Β 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Β 

Β 

Β 

Long

Short

Β 

Β 

Number

(%)

Number

(%)

(1) Relevant securities

Β 

87,272,532 *

1.42

(2) Derivatives (other than options)

Β 

208,388

0.00

(3) Options and agreements to purchase/sell

Β 

Total

Β 

87,480,920 *

1.42

*In addition to the dealings in section 3, there is a reduction in the holding of 184 shares due to a transfer.

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Β 

Class of relevant security:

Β 

Long

Short

Β 

Β 

Number

(%)

Number

(%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Β 

Total

Β 

Β 

Β 

Β 

Β 

3. DEALINGS (Note 4)

Β 

(a) Purchases and sales

Β 

Purchase/sale

Β 

Number of relevant securities

Price per unit

(USD)

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

Β 

Β 

Β 

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Β 

118,756

220

53

41

110

329

75

7

549

314

227,840

Β 

Β 

Β 

492

162

111

106,200

4

3

20

50

4

79,800

551

2,620

13,500

44

63

31

30

148

20

10

27

36,932

38

89

29

166,491

50,784

130

14

176,300

44

25

2,040

15

252

112

4

Β 

32.1650 USD

32.1777 USD

32.2472 USD

32.2473 USD

32.2500 USD

32.2565 USD

32.3000USD

32.3100 USD

32.3600 USD

32.4680 USD

32.8023 USD

Β 

Β 

Β 

31.9990 USD

32.0200 USD

32.0890 USD

32.1159 USD

32.1250 USD

32.1270 USD

32.1280 USD

32.1290 USD

32.1300 USD

32.1450 USD

32.1480 USD

32.1540 USD

32.1932 USD

32.2410 USD

32.2420 USD

32.2450 USD

32.2590 USD

32.2690 USD

32.2700 USD

32.2780 USD

32.2790 USD

32.2920 USD

32.2980 USD

32.2990 USD

32.3000 USD

32.3111 USD

32.3270 USD

32.4890 USD

32.4900 USD

32.6332 USD

32.6690 USD

32.8200 USD

32.8499 USD

32.8900 USD

32.8910 USD

32.8920 USD

32.8930 USD

Β 

Β 

Β Β 

Β 

(b) Derivatives transactions (other than options transactions)

Β 

Product name,

e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (Note 5)

Β 

Β 

Β 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Β 

Product name,

e.g. call option

Β 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 5)

Β 

Β 

(ii) Exercising

Β 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

Β 

Β 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Β 

Nature of transaction (Note 8)

Β 

Details

Price per unit (if applicable) (Note 5)

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Β 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

Β 

Β 

Β 

Is a Supplemental Form 8 attached? (Note 9)

NO

Β 

Date of disclosure

23 November 2015

Contact name

Evangelos Galiatsatos

Telephone number

0207 742 6148

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Β 

Β 

Β 

The Notes on Form 8.3 can be viewed on the Panel's website at www.irishtakeoverpanel.ie.Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEBJBATMBJTBMA
Date   Source Headline
1st Mar 20178:51 amRNSPress Release
27th Feb 201710:45 amRNSPress Release
24th Feb 20172:19 pmRNSPress Release
22nd Feb 20177:00 amRNSCancellation of UK Listing
31st Jan 20172:56 pmRNSFourth Quarter and Full-Year 2016 Results
24th Nov 20153:20 pmRNSForm 8.3 - Pfizer Inc
24th Nov 20153:19 pmRNSForm 8.3 - Pfizer, Inc.
24th Nov 201512:14 pmRNSForm 38.5(b) - Pfizer Inc
24th Nov 201511:49 amRNSForm 8.1a - Pfizer Inc
24th Nov 201511:46 amRNSForm 38.5(a) - Pfizer Inc
24th Nov 201510:41 amRNSRule 38.5 - Pfizer INC
24th Nov 20157:00 amRNSForm 38.5(b) - Pfizer Inc
23rd Nov 20156:11 pmRNSForm 38.5(a) - Pfizer Inc
23rd Nov 20155:58 pmRNSForm 8.1a - Pfizer Inc
23rd Nov 20153:40 pmRNSForm 8.3 - PFIZER INC
23rd Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc Amendment
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:28 pmRNSForm 8.3 - ALLERGAN PLC
23rd Nov 20153:21 pmRNSForm 8.3 - Pfizer, Inc.
23rd Nov 20152:56 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:39 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:29 pmRNSForm 8.3 - Allergan Plc
23rd Nov 201512:16 pmRNSForm 8.1 - [Pfizer Inc.]
23rd Nov 201512:04 pmRNSForm 38.5a
23rd Nov 201511:57 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
20th Nov 20153:43 pmRNSForm 8.3 - Pfizer Inc.
20th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:25 pmRNSForm 8.3 - Allergan plc
20th Nov 20153:21 pmRNSForm 8.3 - PFIZER INC
20th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
20th Nov 20153:14 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:11 pmRNSForm 8.3 - [PFIZER INC]
20th Nov 20153:07 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20152:58 pmRNSForm 8.3 - Allergan plc
20th Nov 20152:57 pmRNSRule 38.5 - Replacement Pfizer INC
20th Nov 20152:52 pmRNSForm 8.3 - Allergan Plc
20th Nov 20152:44 pmRNSForm 8.3 - Pfizer, Inc.
20th Nov 201512:14 pmRNSForm 8.1 - [Pfizer Inc]
20th Nov 201511:57 amRNSForm 38.5b
20th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
20th Nov 201511:53 amRNSForm 38.5b
20th Nov 201511:53 amRNSForm 38.5(b) - Pfizer Inc
20th Nov 201511:52 amRNSForm 38.5a
20th Nov 201511:18 amRNSForm 38.5(a) - Pfizer Inc
20th Nov 201510:37 amRNSRule 38.5 - Pfizer INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.